Global Leukocyte Adhesion Deficiency Management Market 2024 Competitive Landscape, Industry Analysis, Segmentation And Forecast To 2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2101

The Business Research Company offers in-depth market insights through Leukocyte Adhesion Deficiency Management Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The leukocyte adhesion deficiency management market size has grown strongly in recent years. It will grow from $7.48 billion in 2023 to $8.07 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increased awareness and education, genetic testing advancements, orphan drug designations, global health policies, patient advocacy groups, pediatric healthcare advancements..

The leukocyte adhesion deficiency management market size is expected to see strong growth in the next few years. It will grow to $10.46 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to precision medicine approaches, emergence of novel therapeutics, expanded genetic testing accessibility, patient-centric drug development, advancements in immunomodulatory therapies.. Major trends in the forecast period include stem cell transplantation innovations, integration of supportive therapies, telemedicine for remote consultations, collaboration and research networks, integration of biomarker technologies..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13172&type=smp

Market Segmentation:
The leukocyte adhesion deficiency management market covered in this report is segmented -
1) By Treatment: Hematopoietic Stem Cell Transplantation, Recombinant Human Interferon-Gamma Treatment, Prophylactic Immunoglobulin Therapy, Antimicrobial Therapy, Prophylactic Therapy, Fucose Supplementation, Monoclonal Antibodies, Coagulation Factors
2) By Diagnosis: Blood Test, Genetic Testing, Biopsy, Other Types
3) By End-Users: Hospitals, Specialty Clinics, Other End-Users

Major Driver - Leukocyte Adhesion Deficiency Management Market Grows In Response To Rising Prevalence Of Primary Immunodeficiency.
The rising prevalence of primary immunodeficiency is expected to propel the growth of the leukocyte adhesion deficiency management market going forward. Primary immunodeficiency (PID) is a group of inherited disorders that weaken the body's immune system, making individuals more susceptible to infections and illnesses due to defects in their immune responses. Management of leukocyte adhesion deficiency benefits primary immunodeficiency by advancing the understanding of immune system disorders and potentially leading to improved diagnostic tools and therapies to help both conditions. For instance, in April 2023, according to the Peace Hospital, an India-based multi-specialty hospital, the data collected from World Primary Immunodeficiency (WPI) Awareness Week 2023 shows that primary immunodeficiency (PI) affects an estimated 60 lakh people globally, and 70% to 90% of people have undiagnosed primary immunodeficiency. Therefore, the rising prevalence of primary immunodeficiency will drive the growth of the leukocyte adhesion deficiency management market.

Competitive Landscape:
Major companies operating in the leukocyte adhesion deficiency management market report are F. Hoffmann-La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Gilead Sciences Inc, Teva Pharmaceuticals Industries Limited, CSL Behring LLC, Vertex Pharmaceuticals Inc., Grifols International S.A., Aurobindo Pharma Ltd., BioMarin Pharmaceutical Inc., Cadila Healthcare Ltd., Ipca Laboratories Ltd, Sana Biotechnology Inc., Rocket Pharmaceuticals Inc., PT Sanbe Farma, Magenta Therapeutics Inc, Avalo Therapeutics Inc., Aspen Neuroscience Inc., Sandoz International GmbH, Orpha Labs Inc., Swiss Pharm Holding AG, Rubius Therapeutics Inc., Enochian Biosciences Inc., Sigma-Aldrich LLC, Bluebird Bio Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/leukocyte-adhesion-deficiency-management-global-market-report

Top Trend - Leading Companies In The Leukocyte Adhesion Deficiency Management Market Focus On Advanced Therapies Like Rp-L201 To Improve Treatment For Lad-I
Major companies operating in the leukocyte adhesion deficiency management market are focused on developing novel treatments and therapies, such as RP-L201, to address the underlying genetic defects and improve the quality of life for affected individuals. Regenerative Medicine Advanced Therapy (RMAT) for RP-L201 supports the efficient development of advanced gene therapy for treating leukocyte adhesion deficiency-I (LAD-I). For instance, in March 2021, Rocket Pharmaceuticals, Inc., a US-based clinical-stage company, received the U.S. Food and Drug Administration (FDA) designation for Regenerative Medicine Advanced Therapy (RMAT) (RP-L201). The RMAT designation was obtained based on promising preliminary safety and efficacy data from RP-L201's ongoing Phase 1/2 clinical trial. The RMAT designation was created to aid in developing and approving regenerative medicine products such as cell and gene therapies. The designation is given to an investigational product that has the potential to treat, alter, reverse, or cure a serious or life-threatening disease or condition and is supported by preliminary clinical evidence demonstrating its ability to address an unmet medical need.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Leukocyte Adhesion Deficiency Management Market Characteristics
3. Leukocyte Adhesion Deficiency Management Market Trends And Strategies
4. Leukocyte Adhesion Deficiency Management Market - Macro Economic Scenario
5. Leukocyte Adhesion Deficiency Management Market Size And Growth
…..
27. Leukocyte Adhesion Deficiency Management Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.